DeepMed Research

Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Clinical Study of rhTPO in Hematopoietic Stem Cell Mobilization for Autologous Transplantation in Acute Leukemia

Not Applicable

Not yet recruiting

Conditions: Hematopoietic Stem Cell Mobilization

Interventions: Drug: Recombinant Human Thrombopoietin（rhTPO）

First Posted Date: 2025-05-02

Last Posted Date: 2025-05-02

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 60

Registration Number: NCT06955858

Locations: 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, China

CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases

Phase 1

Recruiting

Conditions: SLE
Systemic Sclerosis (SSc)
Inflammatory Myopathy
ANCA-Associated Vasculitis (AAV)

Interventions: Biological: UCAR T-cell

First Posted Date: 2025-04-23

Last Posted Date: 2025-04-23

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 12

Registration Number: NCT06941129

Locations: 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, China

Reproductive and Mental Health of Patients With Aplastic Anemia

Recruiting

Conditions: Aplastic Anemia
Reproductive Health

First Posted Date: 2025-04-20

Last Posted Date: 2025-04-20

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 600

Registration Number: NCT06936930

Locations: 🇨🇳
Regenerative Medicine Center, Tianjin, Tianjin, China

Growth Evaluation, Health Promotion, and Clinical Management in Children and Adolescents With Thalassemia

Not Applicable

Recruiting

Conditions: Thalassemia Intermedia
Thalassemia Major
Growth Delay
Puberty, Delayed

First Posted Date: 2025-04-17

Last Posted Date: 2025-04-17

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 369

Registration Number: NCT06931912

Locations: 🇨🇳
Regenerative Medicine Center and Red Blood Cell Disorders Center, Tianjin, Tianjin, China

Brain Function and Psychological Changes Related to Cell Therapy for Autoimmune Hemolytic Anemia

Recruiting

Conditions: Psychological Well-Being
CAR T-cell Therapy
Autoimmune Hemolytic Anemia
Brain Function

First Posted Date: 2025-04-10

Last Posted Date: 2025-04-10

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 20

Registration Number: NCT06921980

Locations: 🇨🇳
Regenerative Medicine Center, Tianjin, Tianjin, China

Efficacy of Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Bridging Therapy Followed by Transplantation in Higher-Risk Myelodysplastic Syndrome Patients

Phase 2

Not yet recruiting

Conditions: Myelodysplastic Syndromes

First Posted Date: 2025-04-09

Last Posted Date: 2025-04-09

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 236

Registration Number: NCT06918834

Disease Burden Transition of Mucormycosis in Hematologic Malignancies Population Across Covid 19 Era: a Single-center Comparative Analysis From China

Active, not recruiting

Conditions: Mucormycosis
Hematologic Malignancies
COVID-19

First Posted Date: 2025-03-28

Last Posted Date: 2025-03-28

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 60

Registration Number: NCT06900114

Locations: 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, China

Selinexor Combined With Azacitidine Therapy in High-Risk Myeloid Neoplasms Patients

Phase 2

Not yet recruiting

Conditions: Acute Myeloid Leukemia
Myelodysplastic Syndrome
Chronic Myelomonocytic Leukemia

Interventions: Drug: Selinexor

First Posted Date: 2025-03-28

Last Posted Date: 2025-03-28

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 20

Registration Number: NCT06900088

Locations: 🇨🇳
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, China., Tianjin, China

Anti-CD38 Antibody Treating Primary Immune Thrombocytopenia (ITP)

Phase 2

Recruiting

Conditions: Immune Thrombocytopenia
Treatment

Interventions: Drug: Daratumumab Injection

First Posted Date: 2025-03-25

Last Posted Date: 2025-03-25

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 30

Registration Number: NCT06838962

Locations: 🇨🇳
Chinese Academy of Medical Science and Blood Disease Hospital, Tianjin, Tianjin, China

Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol

Phase 2

Not yet recruiting

Conditions: Acute Lymphoblastic Leukemia ALL
Childhood Leukemia, Acute Lymphoblastic
B Cell Acute Lymphoblastic Leukemia (B-ALL)

Interventions: Drug: Blinatumomab
Drug: Reinduction-2 omission
Drug: Chemo-light Maintenance 2

First Posted Date: 2025-03-25

Last Posted Date: 2025-03-25

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 3000

Registration Number: NCT06882057

Locations: 🇨🇳
Anhui Provincial Children's Hospital, Hefei,, Anhui, China
🇨🇳
Anhui Medical University Second Affiliated Hospital, Hefei, Anhui, China
🇨🇳
Chongqing Medical University Affiliated Children's Hospital, Chongqing, Chongqing, China

and more 23 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy